Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.
CRISPR/Cas systems for elimination and targeting HIV-1 provirus
| CRISSPR-Cas system used | Delivery method for CRISPR components | Targeted regions | Cell line or organism studied | Targeted locus | Efficiency | References |
|---|---|---|---|---|---|---|
| SpCas9 | Transfection | LTR (U3 region) | 293T, Jurkat & Hela | 465–484 | 30–90% | [104] |
| SpCas9 | Transfection | LTR (U3 region) | CHME5, TZM-BI, & U937 | 101–127 | 30–90% | [105] |
| SpCas9 | Lentivirus | LTR (R region) | 293T-CD4-CCR5, hPSC, & 293 Primary T cells | 464–486 | 20–90% | [107] |
| SpCas9 | Transfection | Rev (the second exon) | JLat10.6 | 8513–8532 | 30% | [93] |
| SpCas9 | Lentivirus | Gag/ Pol/ Rev/ Env | SupT1 | 2249–2277 | 30–90% | [135] |
| SpCas9 | Lentivirus | LTR (U3 and R region) | J.Lat FL & SupT1 | 300–408 | 35–98% | [108] |